Table 3 Baseline recorded clinical characteristics for men and women aged 35–74 initially free from cardiovascular disease and diabetes in the validation datasets
CharacteristicsQRESEARCH validation cohortTHIN validation cohort
Men(n = 301 622)Women(n = 306 111)Men(n = 529 813)Women (n = 542 987)
Age at baseline, median (interquartile range)47 (40 to 57)49 (41 to 59)48 (40 to 57)49 (41 to 59)
Body mass index (kg/m2), mean (SD)26.5 (4.0)26.1 (4.8)26.6 (4.0)26.1 (4.9)
Systolic blood pressure (mm Hg), mean (SD)135.3 (19.6)132.2 (21.6)135.6 (19.4)132.1 (21.0)
Total serum cholesterol (mmol), mean (SD)5.7 (1.1)5.8 (1.2)5.7 (1.1)5.8 (1.2)
HDL (mmol/l), mean (SD)1.3 (0.4)1.6 (0.4)1.3 (0.4)1.6 (0.4)
Total serum cholesterol/HDL ratio, mean (SD)4.5 (1.3)3.9 (1.2)4.5 (1.3)3.9 (1.2)
Current smoker84 930 (28.2)70 210 (22.9)141 113 (26.6)124 094 (22.9)
Family history of coronary heart disease in first-degree relative under 60 years27 829 (9.2)38 026 (12.4)18 638 (3.5)22 922 (4.2)
Receiving antihypertensive treatment*24 245 (8.0)36 992 (12.1)35 066 (6.6)56 886 (10.5)
Receiving ACE inhibitors*6 898 (2.3)7 170 (2.3)11 718 (2.2)12 901 (2.4)
Receiving β-blockers*11 321 (3.8)17 892 (5.8)16 700 (3.2)27 554 (5.1)
Receiving calcium channel blockers*7 346 (2.4)8 479 (2.8)9 847 (1.9)11 147 (2.1)
Receiving thiazides*6 837 (2.3)14 571 (4.8)10 630 (2.0)23 391 (4.3)
  • Results are shown as counts (%) unless otherwise specified.

  • Patients receiving statins at baseline have been excluded.

  • *At entry to the cohort.